A history of drug advertising: The evolving roles of consumers and consumer protection

Milbank Quarterly

Volumn 84, Issue 4, 2006, Pages 659-699

  Donohue, Julie ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Consumerism; Consumers; Direct to consumer advertising; Food and Drug Administration; Patients; Pharmaceutical industry; Prescription drugs; Regulation; Rights

Indexed keywords

ADVERTIZING; DECISION MAKING; DOCTOR PATIENT RELATION; DRUG INDUSTRY; ETHICS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE POLICY; HISTORY; HUMAN; LEGAL ASPECT; PATIENT PARTICIPATION; PROFESSIONAL PRACTICE; REVIEW; SAFETY; SELF CARE; UNITED STATES;

ADVERTISING; CONSUMER PRODUCT SAFETY; DECISION MAKING; DRUG INDUSTRY; FEDERAL GOVERNMENT; GOVERNMENT REGULATION; HEALTH POLICY; HISTORY, 20TH CENTURY; HUMANS; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PROFESSIONAL AUTONOMY; SELF CARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750601174     PISSN: 0887378X     EISSN: 14680009     Source Type: Journal    
DOI: 10.1111/j.1468-0009.2006.00464.x     Document Type: Review

References (114)

1. Altman, L.K. 1982. Prescription Drugs Are Advertised to Patients, Breaking with Tradition. New York Times, February 23, C1.
2. American Medical Association (AMA), Council on Ethical and Judicial Affairs. 2000. Direct-to-Consumer Advertising of Prescription Drugs. Food and Drug Law Journal 55:119-24.
3. American Medical Association (AMA), House of Delegates. 1989. AMA Policy Compendium: Current Policies of the AMA House of Delegates through the 1989 Interim Meeting / AMA Council on Long Range Planning and Development in Cooperation with the AMA Division of Health Policy Development and the Division of Library and Information Management. Chicago, June.
4. Angell, M. 2004. The Truth about Drug Companies. New York: Random House.
5. Arrow, K.J. 1963. Uncertainty and the Welfare Economics of Medical Care. American Economic Review 53(5):941-73.
6. Basara, L.R. 1992. Direct-to-Consumer Advertising: Today's Issues and Tomorrow's Outlook. Journal of Drug Issues 22(2):317-30.
7. Baumgartner, F., and B. Jones. 1993. Agendas and Instability in American Politics. Chicago: University of Chicago Press.
8. Baumgartner, F., and B.L. Leech. 1996. Lobbying Disclosure Data Set. Advocacy and Public Policy Making Project. Pennsylvania State University. Available at http://lobby.la.psu.edu/related.html (accessed July 27, 2006).
9. Blendon, R.J., and J.M. Benson. 2001. Americans' View on Health Policy: A Fifty Year Historical Perspective. Health Affairs 20(2):33-46.
10. Blendon, R.J., U.S. Szalay, and R.A. Knox. 1992. Should Physicians Aid Their Patients in Dying? Journal of the American Medical Association 267(19):2658-62.
11. Bonaccorso, S.N., and J.L. Sturchio. 2002. For and Against: Direct to Consumer Advertising Is Medicalising Normal Human Experience. British Medical Journal 324(April 13):910-11.
12. Borow, W. 1993. The AMA Explains Its About-face on Direct-to-Consumer Advertising. Medical Marketing and Media 28(9):68.
13. Carpenter, D. 2004. The Political Economy of FDA Drug Review: Processing, Politics and Lessons for Policy. Health Affairs 23(1):52-63.
14. Chadduck, H.W. 1972. "In Brief Summary": Prescription Drug Advertising, 1962-1971. FDA Papers (February):13-25.
15. Clark, M., and S. Agrest. 1975. A Right to Die? Newsweek, November 3, 58.
16. Cohen, E.P. 1988. Direct-to-the-Public Advertisement of Prescription Drugs. New England Journal of Medicine 318(6):373-76.
17. Consumer Reports. 1984. Should Prescription Drugs Be Advertised to Consumers? July, 392-93.
18. Cutrer, C.M., and A.M. Pleil. 1991. Potential Outcomes Associated with Direct-to-Consumer Advertising of Prescription Drugs: A Physician's Perspective. Journal of Pharmaceutical Marketing and Management 5(3):3-19.
19. Eisenberg, D.M., R.B. Davis, S.L. Ettner, S. Appel, S. Wilkey, M.V. Rompay, and R.C. Kessler. 1998. Trends in Alternative Medicine Use in the United States, 1990-1997: Results of a National Follow-up Survey. Journal of the American Medical Association 280(18):1569-75.
20. Epstein, S. 1996. Impure Science: AIDS, Activism and the Politics of Knowledge. Berkeley: University of California Press.
21. Feather, K.R. 1997. Oral History Interview with Ken Feather. Rockville, Md.: U.S. Food and Drug Administration, May 7.
22. Food and Drug Administration (FDA). Statement of Policy. 1983. Direct-to-Consumer Advertising of Prescription Drugs, Moratorium, and Cover Letter, September 2.
23. Food and Drug Administration, Department of Health and Human Services (FDA/DHHS). 1969. Regulations for the Enforcement of the Federal Food, Drug and Cosmetic Act and the Fair Packaging and Labeling Act. Federal Register 34:7802.
24. Food and Drug Administration, Department of Health and Human Services (FDA/DHHS). 1985. Direct-to-Consumer Advertising Moratorium for Prescription Drugs Ended. Federal Register 50:36677.
25. Food and Drug Administration, Department of Health and Human Services (FDA/DHHS). 1995a. FDA Public Hearing, Direct-to-Consumer Promotion, October 18.
26. Food and Drug Administration. Department of Health and Human Services (FDA/DHHS). 1995b. Notice of Public Hearing, Request for Comments, Direct-to-Consumer Promotion, August 16. Federal Register 60:42581.
27. Food and Drug Administration, Department of Health and Human Services (FDA/DHHS). 1997. Draft Guidance for Industry: Broadcast Advertising of Prescription Drugs, August.
28. Food and Drug Administration, Department of Health and Human Services (FDA/DHHS). 1999. Guidance for Industry: Consumer-Directed Broadcast Advertisements, 1999. Available at http://www.fda.gov/cder/guidance/1804fnl.htm (accessed October 2006).
29. Fox, S., and D. Fallows. 2003. Internet Health Resources. Washington, D.C.: Pew Internet and American Life Project, July 16, 2004. Available at http://www.pewinternet.org/PPF/r/183/report display.asp (accessed July 24, 2006).
30. Goodrich, W.W. 1986. Oral History Interview with William W. Goodrich, Office of the General Counsel, 1939-1971. Rockville, Md.: U.S. Food and Drug Administration, October 15. Available at http://www.fda.gov/oc/history/ oralhistories/goodrich/default.htm (accessed July 27, 2006).
31. Haas-Wilson, D. 2001. Arrow and the Information Market Failure in Health Care: The Changing Content and Sources of Health Care Information. Journal of Health Policy Politics and Law 26(5):1031-44.
32. Halpern, S.A. 2004. Medical Authority and the Culture of Rights. Journal of Health Politics Policy and Law 29(4-5):835-52.
33. Harris, G. 2003. States Try to Limit Drugs in Medicaid, but Makers Resist. New York Times, December 18, A1.
34. Harris, R. 1964. The Real Voice. New York: Macmillan.
35. Harvey, L.K., and S.C. Shubat. 1989. Physician and Public Attitudes. Chicago: American Medical Association.
36. Health Action International and the European Public Health Alliance (HAI/EPHA). 2002. Joint Statement on the Proposed Relaxation of the EU Ban on Direct-to-Consumer Advertising of Prescription Medicines. February 4. Available online at http://haiweb.org/campaign/DTCA/jointstatement.html (accessed December 2004).
37. Henney, J.E. 2000. Challenges in Regulating Direct-to-Consumer Advertising. Journal of the American Medical Association 284(17):2242.
38. Hilts, P.J. 2003. Protecting America's Health. New York: Knopf.
39. Holmer, A.F. 1999. Direct-to-Consumer Prescription Drug Advertising Builds Bridges between Patients and Physicians. Journal of the American Medical Association 281(4):380-82.
40. Holmer, A.F. 2002. Direct-to-Consumer Advertising - Strengthening Our Health Care System. New England Journal of Medicine 346(7):526-28.
41. Hurwitz, M.A., and R.E. Caves. 1988. Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals. Journal of Law and Economics 31(October):299-320.
42. Iizuka, T. 2004. What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs? Journal of Industrial Economics 52(3):349-79.
43. IMS Health. 2006. Top Line Industry Data: Total U.S. Promotional Spend by Type, 2005. Available at http://www.imshealth.com/ims/portal/front/articleC/0, 2777,6599_78084568_78152318,00.html (accessed July 23, 2006).
44. Institute of Medicine (IOM). 1979. Evaluating Patient Package Inserts. Washington, D.C.: National Academy of Sciences.
45. Jackson, C.O. 1970. Food and Drug Legislation in the New Deal. Princeton, N.J.: Princeton University Press.
46. Journal of the American Medical Association. 1900. Secret Nostrums and the Journal. June 2:1420.
47. Juhl, R.P. 1998. Prescription to Over-the-Counter Switch: A Regulatory Perspective. Clinical Therapeutics 20 (suppl. C):C111-17.
48. Kaptchuk, T.J., and F.G. Miller. 2005. What Is the Best and Most Ethical Model for the Relationship between Mainstream and Alternative Medicine: Opposition, Integration or Pluralism? Academic Medicine 80(3):286-90.
49. Kassirer, J.P. 1983. Adding Insult to Injury: Usurping Patients' Prerogatives. New England Journal of Medicine 308:898-901.
50. Katz, J. 1972. Experimentation with Human Beings: The Authority of the Investigator, Subject, Professions and the State in the Human Experimentation Process. New York: Russell Sage.
51. Keith, A. 1992. The Benefits of Pharmaceutical Promotion: An Economic and Health Perspective. Journal of Pharmaceutical Marketing & Management 7(1):121-33.
52. Kendellen, R.M. 1985. The Food and Drug Administration Retreats from Patient Package Inserts for Prescription Drugs. Food Drug and Cosmetic Law Journal 40:172-87.
53. Kessler, D.A., and W.L. Pines. 1990. The Federal Regulation of Prescription Drug Advertising and Promotion. Journal of the American Medical Association 264(18):2409-15.
54. Kessler, D.A., J.L. Rose, R.L. Temple, R. Schapiro, and J.P. Griffin. 1994. Therapeutic-Class Wars - Drug Promotion in a Competitive Marketplace. New England Journal of Medicine 331(20):1350-53.
55. Kolata, G. 1983. Prescription Drug Ads Put FDA on the Spot. Science 220(4595):387-88.
56. Kreling, D.H., D.A. Mott, and J.B. Wiederholt. 2001. Prescription Drug Trends: A Chartbook Update, November. Henry J. Kaiser Family Foundation. Available at http://www.kff.org/rxdrugs/upload/Prescription-Drug-Trends-A- Chartbook-Update-Chartbook.pdf (accessed July 27, 2006).
57. Laine, C., and F. Davidoff. 1996. Patient-Centered Medicine: A Professional Evolution. Journal of the American Medical Association 275(2):152-56.
58. Lanier, B. 1982. Drug Company Advertising to the Public. Journal of the American Medical Association 248(10):1163.
59. Ling, D.C., E.R. Berndt, and M.K. Kyle. 2003. Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales. Journal of Law and Economics 45:691-723.
60. Lipsky, M.S., and C.A. Taylor. 1997. The Opinions and Experiences of Family Physicians Regarding Direct-to-Consumer Advertising. Journal of Family Practice 45(6):495-99.
61. Ma, J., R.S. Stafford, I.M. Cockburn, and S.N. Finkelstein. 2003. A Statistical Analysis of the Magnitude and Composition of Drug Promotion in the United States in 1998. Clinical Therapeutics 25:1502-17.
62. Mariner, W.K. 1998. Standards of Care and Standard Form Contracts: Distinguishing Patient Rights and Consumer Rights in Managed Care. Journal of Contemporary Health Law and Policy 15(Fall):1-55.
63. May, C.D. 1961. Selling Drugs by "Educating" Physicians. Journal of Medical Education 36(1):1-23.
64. Merrill, R.A. 1973. Compensation for Prescription Drug Injuries. Virginia Law Review 59(1):1-120.
65. Mintzes, B. 2002. Direct-to-Consumer Advertising Is Medicalising Normal Human Experience. British Medical Journal 324(April 13):908-9.
66. Mishra, R. 2002. Ex-FDA Chief Recants on Drug Advertising: Kessler Tells Industry He Was Wrong to Resist. Boston Globe, April 17, A2.
67. Morris, L.A. 1977. Patient Package Inserts: A Tool for Patient Education. Public Health Reports 92(September/October):421-24.
68. Morris, L.A., D. Brinberg, R. Klimberg, L.G. Millstein, and C. Rivera. 1986a. Consumer Attitudes about Advertisements for Medicinal Drugs. Social Science Medicine 22(6):629-38.
69. Morris, L.A., D. Brinberg, R. Klimberg, C. Rivera, and L.G. Millstein. 1986b. The Attitudes of Consumers toward Direct-to-Consumer Advertising of Prescription Drugs. Public Health Reports 101:82-89.
70. Morris, L.A., and L.G. Millstein. 1984. Drug Advertising to Consumers: Effects of Formats for Magazine and Television Advertisements. Food Drug Cosmetic Law Journal 39:497-503.
71. National Consumers League. 1998. The National Consumers League Direct-to-Consumer Promotion of Prescription Drugs Roundtable 2, Consensus Report, September. Available at http://www.nclnet.org/DTCPconsensus.html (accessed December 28, 2004).
72. National Consumers League. 2003. Press Release: Consumers Taking Control with DTC Rx Ads, January 9. Available at http://www.nclnet.org/dtcpr.htm (accessed December 28, 2004).
73. Neilsen, N.H. 2003. Statement of the American Medical Association: Direct-to-Consumer Advertising of Prescription Drugs: Exploring the Consequences. U.S. Senate Special Committee on Aging, July. Available at http://aging.senate.gov/index.cfm?Fuseaction=Hearings.Detail&HearingID=26 (accessed September 2, 2003).
74. O'Brien, W.M. 1982. Alleged Direct Promotion of Prescription Drugs to Consumers. New England Journal of Medicine 306(3):181-82.
75. Palumbo, F.B., and C.D. Mullins. 2002. The Development of Direct-to-Consumer Prescription Drug Advertising Regulation. Food and Drug Law Journal 57(3):423-44.
76. Parsons, T., and R. Fox. 1952. Illness, Therapy and the Modern Urban American Family. Journal of Social Issues 8:31-44.
77. Pescosolido, B.A., and J.K. Martin. 2004. Cultural Authority and the Sovereignty of American Medicine: The Role of Networks, Class and Community. Journal of Health Politics Policy and Law 29(4-5):735-49.
78. Pescosolido, B.A., S.A. Tuch, and J.K. Martin. 2001. The Profession of Medicine and the Public: Examining Americans' Changing Confidence in Physician Authority from the Beginning of the "Health Care Crisis" to the Era of Health Care Reform. Journal of Health and Social Behavior 42(March):1-16.
79. Peterson, M. 1999. Introduction: Politics, Misperception or Apropos? Journal of Politics Policy and Law 24(5):873-86.
80. Pines, W.L. 1999. A History and Perspective on Direct-to-Consumer Promotion. Food and Drug Law Journal 54:489.
81. Rehder, R.R. 1965. Communication and Opinion Formation in a Medical Community: The Significance of the Detail Man. Academy of Management, December, 282-91.
82. Reinhardt, U. 1999. The Predictable Managed Care Kvetch on the Rocky Road from Adolescence to Adulthood. Journal of Health Politics Policy and Law 24(5):897-910.
83. Robinson, J.C. 2004. Reinvention of Health Insurance in the Consumer Era. Journal of the American Medical Association 291(15):1880-86.
84. Robinson, J.C. 2005. Health Savings Accounts - The Ownership Society in Health Care. New England Journal of Medicine 353(12):1199-1202.
85. Roter, D.L., and J.A. Hall. 1992. Doctors Talking with Patients/Patients Talking with Doctors: Improving Communication in Medical Visits. Westport, Conn.: Auburn House.
86. Rothman, D.J. 1991. Strangers at the Bedside: A History of How Law and Bioethics Transformed Medical Decision Making. New York: Basic Books.
87. Rothman, D.J. 2001. The Origins and Consequences of Patient Autonomy: A 25-Year Retrospective. Health Care Analysis 9:255-64.
88. Ruby, L.A., and M. Montagne. 1991. Direct-to-Consumer Advertising: A Case Study of the Rogaine Campaign. Journal of Pharmacologic Marketing and Management 6(2):21-32.
89. Ruge, R.B. 1969. Regulation of Prescription Drug Advertising: Medical Progress and Private Enterprise. Publishing Entertainment Advertising Law Quarterly 9(3):261-99.
90. Sasich, L.D., and S.M. Wolfe. 1997. Comments on Food and Drug Administration's Draft Guidance for Industry on Direct-to-Consumer Advertising (HRG Publication no.1429). Available at http://www.citizen.org/publications/ print release.cfm?ID=6626 (accessed October 2003).
91. Saul, S. 2005. Senate Leader Calls for Limits on Drug Ads. New York Times, July 2, C13.
92. Schlesinger, M. 2002. A Loss of Faith: The Sources of Reduced Political Legitimacy for the American Medical Profession. The Milbank Quarterly 80(2):185-235.
93. Schmidt, A.M. 1985. Oral History Interview with Alexander M. Schmidt Commissioner of Food and Drugs, 1973-1976. Rockville, Md.: U.S. Food and Drug Administration, March 8-9. Available at http://www.fda.gov/oc/history/ oralhistories/schmidt/default.htm (accessed July 27, 2006).
94. Scott-Levin Associates Inc. 1992. Direct-to-Consumer Advertising of Prescription Drugs. Newtown, Pa.
95. Shearer, G. 2004. Commentary: Defined Contribution Health Plans: Attracting the Healthy and Well-off. Health Services Research 39:4 (part 2) (August):1159-66.
96. Shorter, E. 1991. Doctors and Their Patients. New Brunswick, N.J.: Transaction.
97. Slaughter, E. 2002/2003. Consumer Reaction to DTC Advertising of Prescription Medicines. Prevention Magazine 1-91.
98. Smeeding, J.E. 1990. Direct-to-Consumer Advertising of Prescription Pharmaceuticals: Strategic Issues for the Pharmaceutical Industry. Topics in Hospital Pharmacy Management 10(1):40-64.
99. Sorian, R., and J. Feder. 1999. Why We Need a Patients' Bill of Rights. Journal of Health Politics Policy and Law 24(5):1137-44.
100. Starr, P. 1982. The Social History of American Medicine. New York: Basic Books.
101. Stevens, M.L.T. 1996. The Quinlan Case Revisited: A History of the Cultural Politics of Medicine and the Law. Journal of Health Politics Policy and Law 21(2):347-66.
102. Swann, J.P. 1994. FDA and the Practice of Pharmacy: Prescription Drug Regulation before the Durham-Humphrey Amendment of 1951. Pharmacy in History 36(2):55-70.
103. Swasy, J. 2003. DTC Advertising Physician Survey: GPs vs. Specialists. Presentation at the DTC National Conference in Boston, 2003. Available at http://www.fda.gov/cder/ddmac/presentations.htm (accessed August 28, 2006).
104. Temin, P. 1980. Taking Your Medicine: Drug Regulation in the United States. Cambridge, Mass.: Harvard University Press.
105. Terzian, T.V. 1999. Direct-to-Consumer Prescription Drug Advertising. American Journal of Law and Medicine 25:149-67.
106. Tindle, H.A., R.B. Davis, R.S. Phillips, and D.M. Eisenberg. 2005. Trends in Use of Complementary and Alternative Medicine by U.S. Adults: 1997-2002. Alternative Therapeutic Health Medicine 11(1):42-49.
107. Tomes, N. 2001. Merchants of Health: Medicine and Consumer Culture in the United States, 1900-1940. Journal of American History 88(2):519-47.
108. Tomes, N. 2006. The Patient as a Policy Factor: A Historical Case Study of the Consumer/Survivor Movement in Mental Health. Health Affairs 25(3):720-29.
109. U.S. Congress, House of Representatives, Committee on Energy and Commerce, Subcommittee on Oversight and Investigations. 1984. Staff Report on Prescription Drug Advertising to Consumers. Washington, D.C.: U.S. Government Printing Office, September, H362-16.
110. Weissman, J.S., D. Blumenthal, A.J. Silk, K. Zapert, M. Newman, and R. Leitman. 2003. Consumers' Reports on the Health Effects of Direct-to-Consumer Drug Advertising. Health Affairs. Web exclusive, February 26.
111. Wolfe, S.M. 2002. Direct-to-Consumer Advertising: Education or Emotion Promotion? New England Journal of Medicine 346(7):524-26.
112. Woodcock, J. 2003. Director, Center for Drug Evaluation and Research, Food and Drug Administration. Speech at the FDA Public Meeting on Direct-to-Consumer Promotion. September 22-23, 2003. Washington, D.C. Transcript available at http://www.fda.gov/cder/ddmac/DTCmeeting2003.html (accessed August 28, 2006).
113. Young, J.H. 1961. The Toadstool Millionaires: A Social History of Patent Medicines in America before Federal Regulation. Princeton, N.J.: Princeton University Press.
114. Young, J.H. 1981. The Long Struggle for the 1906 Law. FDA Consumer, June.